Surrozen, Inc

SRZNNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

11.8M

on 2026-06-30, from 2.11M on 2024-03-31 10-Q ↗

Newest

$200.0M

S-3 of 2026-03-23. 1 prospectus supplement filed under it since. S-3 ↗

$50.0M

TD Securities (USA), agreement of 2026-03-23. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

12.22M

Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $172.50. 10-Q ↗

Cash

11.7 quarters

$102.0M on 2026-06-30 ÷ $8.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 11 of its filings are not read yet.